Cure8 research brief
Disease-related changes in liver drug-metabolizing enzymes may alter how herbal formulas or medications are processed in people with UC, potentially affecting efficacy or safety. Understanding the mechanisms helps inform future research on drug–disease interactions.
Researchers studying drug metabolism, pharmacologists, clinicians interested in drug–disease interactions in IBD, and researchers of herbal/traditional medicine pharmacokinetics.
The researchers compared hepatic microsome metabolism of six main LDXYF components between control and UC mice using high-resolution mass spectrometry, enzyme inhibition assays, molecular docking, and expression analyses (RT-qPCR and Western blot).
They report that many metabolic reactions (hydrogenation, carboxylation, hydroxylation, demethylation) were reduced in UC mice and identified CYP2D22 and CYP2C29 as key isoforms for several components.
The paper also found reduced hepatic expression of CYP2D22 and CYP2C29 in UC mice, along with lower levels of FXR and PXR and the transcription factor HNF4α, suggesting an FXR/PXR–CYP450 signaling change that could explain altered drug/herbal metabolism.
This is an abstract-level report of mechanistic preclinical research in mice using an herbal prescription; it does not provide clinical data in humans. Translation to patient care would require further studies.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to...
The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point...
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
